Skip to main content
SpringerLink
Log in

Insulin is an important risk factor of endometrial cancer among premenopausal women: a case-control study in China

  • Original Article
  • Published:
Tumor Biology

Abstract

The aim of the article was to evaluate the important role played by insulin in the development of endometrial cancer (EC) among Chinese premenopausal women. In this study, 128 endometrial cancer patients and 294 controls who were all premenopausal were included. Baseline characteristics data were collected and serum insulin, C-peptide, sex hormone-binding globulin, C-reaction protein, interleukin-6, and tumor necrosis factor-α levels were measured. Paired t test, χ2 test, Spearman correlation coefficients, and univariate and multivariate logistic regression models were used in data analysis. Furthermore, insulin levels were categorized into quartiles, and likelihood ratio was calculated for the four categories. Blood insulin levels of the patients were significantly higher than those of the controls (P < 0.001). Factor analysis identified insulin (OR = 2.46; 95 % confidence interval (CI) = 1.55–3.91; P < 0.001) as the independent risk factor of EC. When insulin levels were categorized into quartiles, we found that insulin was positively associated with endometrial cancer risk [HR comparing extreme quartiles (HR q4-q1) = 4.44; 95 % CI = 2.59–7.62; P trend = 0.025]. After adjustment for body mass index (BMI) or waist-hip ratio (WHR), this association was attenuated, but still significant. In conclusion, insulin plays an important role in the carcinogenesis of EC among premenopausal women. Treatment targeting down-regulation of blood insulin levels seems effective in the prevention of this malignancy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Henderson BE, Ross RK, Pike MC, Casagrande JT. Endogenous hormones as a major factor in human cancer. Cancer Res. 1982;42:3232–9.

    CAS  PubMed  Google Scholar 

  2. Key TJ, Pike MC. The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer. 1988;57:205–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the million women study. Lancet. 2005;365:1543–51.

    Article  PubMed  Google Scholar 

  4. Mu N, Zhu Y, Wang Y, Zhang H, Xue F. Insulin resistance: a significant risk factor of endometrial cancer. Gynecol Oncol. 2012;125:751–7.

    Article  CAS  PubMed  Google Scholar 

  5. Wang T, Rohan TE, Gunter MJ, Xue X, Wactawski-Wende J, Rajpathak SN, et al. A prospective study of inflammation markers and endometrial cancer risk in postmenopausal hormone nonusers. Cancer Epidemiol Biomarkers Prev. 2011;20:971–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Dossus L, Rinaldi S, Becker S, Lukanova A, Tjonneland A, Olsen A, et al. Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study. Endocr Relat Cancer. 2010;17:1007–19.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Saltzman BS, Doherty JA, Hill DA, Beresford SA, Voigt LF, Chen C, et al. Diabetes and endometrial cancer: an evaluation of the modifying effects of other known risk factors. Am J Epidemiol. 2008;167:607–14.

    Article  PubMed  Google Scholar 

  8. Cote ML, Ruterbusch JJ, Ahmed Q, Bandyopadhyay S, Alosh B, Abdulfatah E, et al. Endometrial cancer in morbidly obese women: do racial disparities affect surgical or survival outcomes? Gynecol Oncol. 2014;133:38–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Cincin ZB, Iyibozkurt AC, Kuran SB, Cakmakoglu B. DNA repair gene variants in endometrial carcinoma. Med Oncol. 2012;29:2949–54.

    Article  CAS  PubMed  Google Scholar 

  10. Canaani J, Ilan N, Back S, Gutman G, Vlodavsky I, Grisaru D. Heparanase expression increases throughout the endometrial hyperplasia-cancer sequence. Int J Gynaecol Obstet. 2008;101:166–71.

    Article  CAS  PubMed  Google Scholar 

  11. Santala S, Talvensaari-Mattila A, Soini Y, Santala M. Prognostic value of cyclin B in endometrial endometrioid adenocarcinoma. Tumour Biol. 2015;36:953–7.

    Article  CAS  PubMed  Google Scholar 

  12. Dossus L, Lukanova A, Rinaldi S, Allen N, Cust AE, Becker S, et al. Hormonal, metabolic, and inflammatory profiles and endometrial cancer risk within the epic cohort—a factor analysis. Am J Epidemiol. 2013;177:787–99.

    Article  PubMed  Google Scholar 

  13. Iozzo P. Viewpoints on the way to the consensus session: where does insulin resistance start? The adipose tissue. Diabetes Care. 2009;32 Suppl 2:S168–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000;106:171–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Zamboni M, Armellini F, Cominacini L, Turcato E, Todesco T, Bissoli L, et al. Obesity and regional body-fat distribution in men: separate and joint relationships to glucose tolerance and plasma lipoproteins. Am J Clin Nutr. 1994;60:682–7.

    CAS  PubMed  Google Scholar 

  16. Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab. 1988;67:460–4.

    Article  CAS  PubMed  Google Scholar 

  17. Ogawa K, Sun C, Horii A. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade. Oncol Rep. 2005;14:1481–5.

    CAS  PubMed  Google Scholar 

  18. Bailyes EM, Nave BT, Soos MA, Orr SR, Hayward AC, Siddle K. Insulin receptor/IGF-1 receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem J. 1997;327(Pt 1):209–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4:505–18.

    Article  CAS  PubMed  Google Scholar 

  20. Lathi RB, Hess AP, Tulac S, Nayak NR, Conti M, Giudice LC. Dose-dependent insulin regulation of insulin-like growth factor binding protein-1 in human endometrial stromal cells is mediated by distinct signaling pathways. J Clin Endocrinol Metab. 2005;90:1599–606.

    Article  CAS  PubMed  Google Scholar 

  21. Mawson A, Lai A, Carroll JS, Sergio CM, Mitchell CJ, Sarcevic B. Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in mcf-7 breast cancer cells through differential regulation of c-myc and cyclin d1. Mol Cell Endocrinol. 2005;229:161–73.

    Article  CAS  PubMed  Google Scholar 

  22. Friedenreich CM, Langley AR, Speidel TP, Lau DC, Courneya KS, Csizmadi I, et al. Case-control study of markers of insulin resistance and endometrial cancer risk. Endocr Relat Cancer. 2012;19:785–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:921–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Lof M, Sandin S, Hilakivi-Clarke L, Weiderpass E. Birth weight in relation to endometrial and breast cancer risks in Swedish women. Br J Cancer. 2007;96:134–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecology and Obstetrics, First People’s Hospital of Laishan District, Yantai, Shandong Province, China, 264003

    Yanli Shao

  2. Department of Gynecology and Obstetrics, Heze Municipal Hospital, Heze, Shandong Province, China, 274031

    Shijie Cheng

  3. Department of Gynecology and Obstetrics, Yantai Yuhuangding Hospital, NO 20, Yuhuangding East Road, Zhifu District, Yantai, Shandong Province, China, 264000

    Jianqing Hou, Ying Zuo, Wei Zheng, Min Xia & Nan Mu

Authors
  1. Yanli Shao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shijie Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jianqing Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ying Zuo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wei Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Min Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nan Mu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Min Xia or Nan Mu.

Ethics declarations

Conflicts of interest

None

Additional information

Yanli Shao and Shijie Cheng contributed equally to the preparation of the current article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shao, Y., Cheng, S., Hou, J. et al. Insulin is an important risk factor of endometrial cancer among premenopausal women: a case-control study in China. Tumor Biol. 37, 4721–4726 (2016). https://doi.org/10.1007/s13277-015-4229-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-4229-x

Keywords

Search

Navigation